Estrogens and Parkinson's disease

Session, Donna R.; Pearlstone, M.M.; Jewelewicz, Raphael; Kelly, A.C.

doi:10.1016/0306-9877(94)90133-3

Cited by 43 publications

(26 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Estrogen therapy was reported to be beneficial for parkinsonian symptoms in some trials [15,16]. In others, however, PD symptoms did not change by estrogen [14], or sometimes even a decrease in estrogen improved the PD symptoms [21]. No significant correlation was observed between parkinsonian symptoms and the levels of estrogen and progesterone [22].…”

Section: Discussionmentioning

confidence: 74%

Female Preponderance of Parkinson’s Disease in Japan

Kimura¹,

Kurimura²,

Wada³

et al. 2002

Neuroepidemiology

View full text Add to dashboard Cite

A male preponderance of Parkinson’s disease (PD) has been reported in European countries and the USA. To verify this issue in Japanese patients with PD, we examined the age- and gender-specific prevalence of PD in Yamagata Prefecture (population 1,244,040), Japan. The prevalence of PD was 61.3/100,000 men and 91.0/100,000 women, showing that women were significantly more affected by PD than men (p < 0.001). Contrary to the findings in Europe and the USA, the results indicate a female preponderance of PD among the Japanese population.

show abstract

Section: Discussionmentioning

confidence: 74%

Female Preponderance of Parkinson’s Disease in Japan

Kimura¹,

Kurimura²,

Wada³

et al. 2002

Neuroepidemiology

View full text Add to dashboard Cite

show abstract

“…Symptoms of PD as well as levodopa-induced dyskinesias have also been shown to be modulated by estrogens [5,[223][224][225]. Many of these studies are based on the effect of estrogen replacement therapy on the response of parkinsonian patients to standard levodopa therapy and generally support an Most of the aforementioned effects of estrogens are though to be mediated by the interaction with estrogen receptors in the brain.…”

Section: Parkinson's Diseasementioning

confidence: 95%

“…Many of these studies are based on the effect of estrogen replacement therapy on the response of parkinsonian patients to standard levodopa therapy and generally support an Most of the aforementioned effects of estrogens are though to be mediated by the interaction with estrogen receptors in the brain. Both α and β estrogen receptors have been detected in various brain structures, including regions involved in memory and cognition such as the hippocampus, the amygdala and the lateral septal nucleus, either in antidopaminergic effect of estrogens on parkinsonian symptoms [224]. However, a recent study suggests that estrogen replacement therapy might be beneficial to women with early PD prior to the initiation of levodopa [226].…”

Section: Parkinson's Diseasementioning

confidence: 97%

Drugs with Estrogen-like Potency and Brain Activity Potential Therapeutic Application for the CNS

Cyr¹,

Calon²,

Morissette³

et al. 2000

CPD

102

View full text Add to dashboard Cite

Numerous reports, ranging from molecular investigations to clinical studies, demonstrate the potency of estrogens to modulate brain function and their implications in schizophrenia and depression. Alterations of dopaminergic, cholinergic, GABAergic, glutamatergic and serotonergic neurotransmission through estrogen-mediated mechanisms have been consistently established. Moreover, studies using in vivo and in vitro models as well as epidemiological data suggest that estrogens provide neuroprotection of central nervous system (CNS) cells implicated in the etiology of neurodegenerative disorders such as Alzheimer s (AD) and Parkinson s (PD) diseases. Numerous genomic or non-genomic mechanisms of actions of estrogens in the brain have been documented implicating classical nuclear estrogen receptors as well as possible estrogen membrane receptors, antioxidant activity of steroids, their effect on fluidity as well as on antiapoptotic proteins and growth factors. Selective estrogen receptor modulators (SERMs) have estrogenic and/or antiestrogenic activity depending on the target tissue. Hence, SERMs have the same beneficial effect as estrogen in skeleton and cardiovascular systems but act as antagonists in breast and uterus. The finding of beneficial side effects of SERMs in the CNS might improve their risk-benefit ratio in traditional indications. In this review, we will survey schizophrenia and depression as examples of mental diseases and AD and PD as neurodegenerative diseases. We will review brain effects of estrogens, steroids possibly acting as pro-drugs of estrogens such as testosterone and dehydroepiandrosterone (DHEA) and present novel findings with SERMs. Drugs with estrogen activity in the brain may have therapeutic potential either by modulating brain neurotransmitter transmission or through neuroprotective activity.

show abstract

“…All other current medications for PD are symptomatic treatments that hardly prevent the progression of PD. An important observation is highly notable that ER agonists modulate the dopaminergic neurotransmission and may be used to alleviate major symptoms of PD (Session et al, 1994; Giladi et al, 1995). Another study reported that estrogen therapy could lower the severity of initial phase of PD at least prior to administration of L-dopa in PD women (Saunders-Pullman et al, 1999), indicating that estrogen and ER agonists could be useful therapy in PD patients.…”

Section: Potential Therapeutic Effects Of Er Agonists In Cns Disormentioning

confidence: 99%

Estrogen receptor agonists for attenuation of neuroinflammation and neurodegeneration

Chakrabarti

Haque

Banik

et al. 2014

Brain Research Bulletin

100

View full text Add to dashboard Cite

Recent results from laboratory investigations and clinical trials indicate important roles for estrogen receptor (ER) agonists in protecting the central nervous system (CNS) from noxious consequences of neuroinflammation and neurodegeneration. Neurodegenerative processes in several CNS disorders including spinal cord injury (SCI), multiple sclerosis (MS), Parkinson's disease (PD), and Alzheimer's disease (AD) are associated with activation of microglia and astrocytes, which drive the resident neuroinflammatory response. During neurodegenerative processes, activated microglia and astrocytes cause deleterious effects on surrounding neurons. The inhibitory activity of ER agonists on microglia activation might be a beneficial therapeutic option for delaying the onset or progression of neurodegenerative injuries and diseases. Recent studies suggest that ER agonists can provide neuroprotection by modulation of cell survival mechanisms, synaptic reorganization, regenerative responses to axonal injury, and neurogenesis process. The anti-inflammatory and neuroprotective actions of ER agonists are mediated mainly via two ERs known as ERα and ERβ. Although some studies have suggested that ER agonists may be deleterious to some neuronal populations, the potential clinical benefits of ER agonists for augmenting cognitive function may triumph over the associated side effects. Also, understanding the modulatory activities of ER agonists on inflammatory pathways will possibly lead to the development of selective anti-inflammatory molecules with neuroprotective roles in different CNS disorders such as SCI, MS, PD, and AD in humans. Future studies should be concentrated on finding the most plausible molecular pathways for enhancing protective functions of ER agonists in treating neuroinflammatory and neurodegenerative injuries and diseases in the CNS.

show abstract

Estrogens and Parkinson's disease

Cited by 43 publications

References 16 publications

Female Preponderance of Parkinson’s Disease in Japan

Female Preponderance of Parkinson’s Disease in Japan

Drugs with Estrogen-like Potency and Brain Activity Potential Therapeutic Application for the CNS

Estrogen receptor agonists for attenuation of neuroinflammation and neurodegeneration

Contact Info

Product

Resources

About